iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Update

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 57,108 shares, a drop of 47.3% from the June 30th total of 108,461 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average daily trading volume, of 69,290 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management bought a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,481 shares of the company’s stock, valued at approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Trading Down 0.9%

Shares of IDNA traded down $0.30 during trading hours on Wednesday, reaching $32.15. The stock had a trading volume of 29,473 shares, compared to its average volume of 43,384. The firm has a 50-day simple moving average of $31.52 and a 200 day simple moving average of $30.15. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $20.93 and a 12 month high of $34.97. The company has a market capitalization of $189.69 million, a price-to-earnings ratio of 14.76 and a beta of 0.92.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.